EGFR and non-small cell lung carcinoma: As observed in a study comparing the clinical efficacy of icotinib and gefitinib in previously treated patients with advanced NSCLC, the therapeutic efficacy of TKIs is better in patients harboring the EGFR exon 19 deletion than in patients harboring the p.L858R mutation.